ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price10.32 USD
Ethical score91.4/100
RatingFAIR VALUE
Our investment reviews on this name
2026-10-18Read Markup10.56-2.3% to today Markdown gives way to Markup after a 6% rise in 7 days
2026-10-11Read Markdown9.97+3.5% to today Accumulation gives way to Markdown first Markdown read since September
2026-10-02Read Accumulation9.97+3.5% to today ✓Markdown gives way to Accumulation
2026-09-01Read Markdown10.13+1.9% to today Markup gives way to Markdown after a 5% rise in 9 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
ImmuCell Corporation holds its Markup at $10.32. The statistical read favours the buyers, held for 8 days.
As held on the ledger · 2026-10-29
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 8 days
Price at the screen
$10.32
Valuation
146.57 trailing · -93.27 forward price to earnings
Values screen
PASS· score 91.4
Beta
0.57
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
17.66%
Below 33%
Interest-bearing debt is just 17.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
5.09%
Below 33%
Cash held in interest-bearing accounts and securities is 5.1% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.57%
Below 5%
Only 0.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
ImmuCell clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 18%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ICCC's ethical verdict changes
Today ICCC passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-29 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ICCC trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-18Markup · changed$10.56+5.9%Entry 8
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.9% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 38%.
2026-10-11Markdown · changed$9.97+0.0%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 38%.
2026-10-02Accumulation · changed$9.97-1.6%Entry 6
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 38%.
2026-09-01Markdown · changed$10.13-8.9%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.9% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 38%.
2026-08-02Markup$11.13+15.8%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 38%.
2026-07-18Markup$9.61+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 60% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 38%.
2026-07-03Markup$9.61+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (91). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$9.61Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (91). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.